Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.64 |
| ▸ | F10 | P00742 | 13/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6108839 | 0.94 | CHRM3 (0.57) | CHRM2CHRM1CHRM3F10SMN1; SMN2 | |
| SCHEMBL6108672 | 0.85 | F10 (0.56) | CHRM3F10NPC1ALOX15HTT | |
| SCHEMBL6107404 | 0.85 | NPC1 (0.52) | CHRM2CHRM1CHRM3F10NPC1 | |
| Hydrochloric Acid SCHEMBL6106700 | 0.85 | F10 (0.58) | CHRM3F10NPC1ALOX15HTT | |
| SCHEMBL6107029 | 0.84 | F10 (0.55) | F10NPC1ALOX15HTTRAB9A | |
| SCHEMBL6107073 | 0.82 | F10 (0.48) | F10 | |
| SCHEMBL6106846 | 0.82 | BCHE (0.52) | CHRM3F10 | |
| Trifluoroacetic Acid SCHEMBL6110275 | 0.79 | F10 (0.51) | CHRM3F10NPC1ALOX15HTT | |
| Hydrochloric Acid SCHEMBL6106707 | 0.79 | F10 (0.50) | F10NPC1ALOX15HTTRAB9A | |
| SCHEMBL6107083 | 0.78 | F10 (0.47) | F10NPC1ALOX15HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129245-B2 | Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots | ELI LILLY AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| EP-1140903-B1 | AROMATIC AMIDES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6759414-B2 | ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | CHRM2 3401/4885CHRM1 3059/4885CHRM3 4142/4885 |
| US-20050282862-A1 | Aromatic amides | F11, F12, F5 | CHRM2 3401/4885CHRM1 3059/4885CHRM3 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.